Novogen Limited (NVGN) Earning Somewhat Favorable News Coverage, Study Shows
Media stories about Novogen Limited (NASDAQ:NVGN) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novogen Limited earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.9772577952234 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of equities research analysts have commented on NVGN shares. Zacks Investment Research upgraded Novogen Limited from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. ValuEngine cut Novogen Limited from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st.
Novogen Limited (NVGN) traded up $0.26 during trading on Tuesday, reaching $2.94. The company’s stock had a trading volume of 6,207 shares, compared to its average volume of 5,347. Novogen Limited has a 52 week low of $1.63 and a 52 week high of $7.60.
COPYRIGHT VIOLATION WARNING: “Novogen Limited (NVGN) Earning Somewhat Favorable News Coverage, Study Shows” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://theolympiareport.com/2017/11/07/novogen-limited-nvgn-earning-somewhat-favorable-news-coverage-study-shows.html.
About Novogen Limited
Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.
Receive News & Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.